Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Cornea ; 41(5): 627-629, 2022 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-34620766

RESUMO

PURPOSE: The aim of this study was to report a unique case of unilateral neurogenic dry eye disease (DED) secondary to isolated parasympathetic denervation of the lacrimal gland along with a literature review. METHOD: This is a case report and literature review on neurogenic DED discussing its clinical presentation, etiology, and treatment options. RESULTS: A 32-year-old woman with hypothyroidism presented with pain and a burning sensation in her left eye and dry nares for 1 week. Ocular examination revealed conjunctival congestion and inferior superficial punctate fluorescein staining in the left eye. Her unanesthetized Schirmer values were 24 and 01 mm in the right and left eyes, respectively, with no secretory activity noted in the left lacrimal gland on direct assessment. A detailed neurologic examination, autoimmune panel, and neuroimaging were unremarkable except for the dry left nasal cavity. She is currently using lubricants and did not consent to pilocarpine therapy. Her lacrimal gland activity was unchanged till 3 months of follow-up. The most common cause of neurogenic DED is idiopathic, followed by trauma. Pilocarpine therapy, in oral, topical, or combined form, has improved tear secretion in 63% of neurogenic DED seen in animal cohort. CONCLUSIONS: Unilateral neurogenic DED can occur as an isolated parasympathetic denervation of the lacrimal glands. Pilocarpine therapy has shown some efficacy in animal cohort of neurogenic DED; however, it needs to be explored for human eyes.


Assuntos
Síndromes do Olho Seco , Hipotireoidismo , Aparelho Lacrimal , Animais , Modelos Animais de Doenças , Síndromes do Olho Seco/diagnóstico , Síndromes do Olho Seco/etiologia , Síndromes do Olho Seco/cirurgia , Feminino , Humanos , Hipotireoidismo/complicações , Aparelho Lacrimal/cirurgia , Parassimpatectomia/efeitos adversos , Lágrimas
2.
Int J Chron Obstruct Pulmon Dis ; 13: 2163-2172, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30038492

RESUMO

Background: Targeted lung denervation (TLD) is a novel bronchoscopic therapy for COPD which ablates parasympathetic pulmonary nerves running along the outside of the two main bronchi with the intent of inducing permanent bronchodilation. The goal of this study was to evaluate the feasibility and long-term safety of bilateral TLD during a single procedure. Patients and methods: This prospective, multicenter study evaluated 15 patients with moderate-to-severe COPD (forced expiratory volume in 1 s [FEV1] 30%-60%) who underwent bilateral TLD treatment following baseline assessment without bronchodilators. The primary safety end point was freedom from documented and sustained worsening of COPD directly attributable to TLD up to 1 year. Secondary end points included technical feasibility, change in pulmonary function tests, exercise capacity, and health-related quality of life. Follow-up continued up to 3 years for subjects who reconsented for longer-term follow-up. Results: A total of 15 patients (47% male, age 63.2±4.0 years) underwent TLD with a total procedure time of 89±16 min, and the total fluoroscopy time was 2.5±2.7 min. Primary safety end point of freedom from worsening of COPD was 100%. There were no procedural complications reported. Results of lung function analysis and exercise capacity demonstrated similar beneficial effects of TLD without bronchodilators, when compared with long-acting anticholinergic therapy at 30 days, 180 days, 365 days, 2 years, and 3 years post-TLD. Five of the 12 serious adverse events that were reported through 3 years of follow-up were respiratory related with no events being related to TLD therapy. Conclusion: TLD delivered to both lungs in a single procedure is feasible and safe with few respiratory-related adverse events through 3 years.


Assuntos
Pulmão/inervação , Parassimpatectomia/métodos , Doença Pulmonar Obstrutiva Crônica/cirurgia , Broncodilatadores , Tolerância ao Exercício , Estudos de Viabilidade , Feminino , Volume Expiratório Forçado , Humanos , Masculino , Pessoa de Meia-Idade , Parassimpatectomia/efeitos adversos , Estudos Prospectivos , Qualidade de Vida , Fatores de Tempo , Resultado do Tratamento
3.
Cardiovasc Pathol ; 21(1): 39-45, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-21353601

RESUMO

BACKGROUND: Recent studies demonstrated that atrial fibrillation (AF) induced heterogeneous sympathetic hyperinnervation and baroreflex impartation, but the changes of vagal and afferent nerve are not clear. METHODS: Six dogs underwent atrial pacing at 600 beats/min (AF group). All paced dogs developed sustained AF by 5 weeks of pacing. Tissues from six healthy dogs were used as controls. Immunohistochemistry staining of cardiac nerves was performed using anti-growth-associated protein 43 (anti-GAP43), anti-tyrosine hydroxylase, antiacetylcholine (anti-ACh), and anti-substance P (anti-SP) antibodies. RESULTS: In AF group, the density of GAP43-positive in the right atrium (RA), atrial septum (AS), and left atrium (LA) was 5590.24±1417.51, 8083.22±1271.39, and 10854.56±1877.56 µm(2)/mm(2), respectively, which was significantly (P<.01) higher than the control group. Most of the newly sprouting nerves are sympathetic nerve. Sympathetic nerve density in AF group was significantly higher than that of control group (P<.001). Whereas denervation of parasympathetic and SP-immunoreactive nerve occurred in AF group. In the dogs with AF, the density of ACh-positive nerve in the RA, AS, and LA was 506.04±104.44, 317.72±84.10, and 114.9±29. 62 µm(2)/mm(2), respectively, which was lower than the control group (P<.01). At the same time, the density of SP-positive nerve in the atria of AF dogs was also significantly lower than the control tissues (P<.01). CONCLUSION: AF led to significant nerve sprouting and sympathetic hyperinnervation in the canine models, but the newly sprouting nerve did not include parasympathetic and SP-immunoreactive nerve. Heterogeneous parasympathetic and SP-immunoreactive nerve denervation occurred in the AF dogs.


Assuntos
Fibrilação Atrial/patologia , Neurotransmissores/metabolismo , Parassimpatectomia/efeitos adversos , Substância P/metabolismo , Animais , Fibrilação Atrial/etiologia , Fibrilação Atrial/metabolismo , Septo Interatrial/inervação , Septo Interatrial/metabolismo , Septo Interatrial/patologia , Biomarcadores/metabolismo , Estimulação Cardíaca Artificial/efeitos adversos , Modelos Animais de Doenças , Cães , Feminino , Proteína GAP-43/metabolismo , Coração/inervação , Átrios do Coração/inervação , Átrios do Coração/metabolismo , Átrios do Coração/patologia , Masculino , Neurônios/metabolismo , Neurônios/patologia , Sistema Nervoso Simpático/metabolismo , Sistema Nervoso Simpático/patologia
4.
Am J Ophthalmol ; 132(1): 106-8, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11438063

RESUMO

PURPOSE: To present a case of bilateral neurotrophic keratopathy with miosis after bilateral Vidian neurectomy for vasomotor rhinitis. METHODS: Observational case report. RESULTS: A 68 year-old man presented with irritation and blurred vision in both eyes 2 weeks after bilateral Vidian neurectomy. Slit-lamp examination revealed a large epithelial defect, typical of neurotrophic keratopathy, in the inferior two-thirds of cornea in both eyes. Corneal sensitivity test with a Cochet-Bonnet anesthesiometer and electrical study of the blink reflex indicated bilateral trigeminal dysfunction. Both pupils were miotic, and tests with hydroxyamphetamine 1% and epinephrine 0.1% showed postganglionic sympathetic nerve damage. The corneal epithelial defects healed after 2 months of treatment with systemic prednisolone, vitamin B(12) and tarsorrhaphy. CONCLUSION: Neurotrophic keratopathy associated with dry eye syndrome may be a serious complication of Vidian neurectomy.


Assuntos
Córnea/inervação , Doenças da Córnea/etiologia , Mucosa Nasal/inervação , Parassimpatectomia/efeitos adversos , Sistema Nervoso Parassimpático/cirurgia , Doenças do Nervo Trigêmeo/etiologia , Idoso , Cefaleia/etiologia , Humanos , Masculino , Miose/etiologia , Rinite Vasomotora/cirurgia
5.
Auton Neurosci ; 83(1-2): 49-57, 2000 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-11023628

RESUMO

Innervation of rat submandibular and parotid glands by the autonomic nervous system regulates saliva volume, its rate of secretion and its composition. The autonomic nervous system also plays a regulatory role in the differentiation and growth of salivary glands, and in the expression of specific sets of genes. Rat cystatin S, a member of family 2 of the cysteine proteinase inhibitor superfamily, is expressed in submandibular and parotid glands of human and rat. In the rat, cystatin S gene expression is tissue- and cell type-specific, is temporally regulated during postnatal development, and not observed in adult animals. The beta-adrenergic agonist isoproterenol (IPR) induces hypertrophic and hyperplastic enlargements of rat salivary glands and the expression of a number of genes including cystatin S. Sympathectomy reduces, but does not completely block, IPR-induced expression of the cystatin S gene in submandibular glands of adult female rats, indicating the participation of sympathetic factor(s) in its regulation. Bilateral parasympathectomy also reduces IPR-induced cystatin S gene expression, suggesting a role of the parasympathetic nervous system in its regulation. Experiments described in this paper suggest that similar factor(s) arising from both the sympathetic and parasympathetic branches of the autonomic nervous system simultaneously participate in IPR-induced cystatin S gene expression in submandibular glands.


Assuntos
Vias Autônomas/metabolismo , Cistatinas/genética , Regulação da Expressão Gênica/fisiologia , Glândula Submandibular/inervação , Animais , Vias Autônomas/citologia , Vias Autônomas/efeitos dos fármacos , Tamanho Celular/fisiologia , Feminino , Lateralidade Funcional/fisiologia , Hipertrofia/etiologia , Hipertrofia/fisiopatologia , Isoproterenol/farmacologia , Tamanho do Órgão/fisiologia , Parassimpatectomia/efeitos adversos , Fibras Parassimpáticas Pós-Ganglionares/citologia , Fibras Parassimpáticas Pós-Ganglionares/efeitos dos fármacos , Fibras Parassimpáticas Pós-Ganglionares/metabolismo , Ratos , Ratos Sprague-Dawley , Cistatinas Salivares , Glândula Submandibular/citologia , Glândula Submandibular/efeitos dos fármacos , Glândula Submandibular/metabolismo , Simpatectomia/efeitos adversos , Fibras Simpáticas Pós-Ganglionares/citologia , Fibras Simpáticas Pós-Ganglionares/efeitos dos fármacos , Fibras Simpáticas Pós-Ganglionares/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA